Studying Cognition in SPG4

NCT ID: NCT03104088

Last Updated: 2020-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-10

Study Completion Date

2017-12-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparing the cognitive levels of patients with SPG4 mutations to healthy controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Comparing the cognitive levels of patients with SPG4 mutations to healthy controls by using the CANTAB® and MoCA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Impairment Hereditary Spastic Paraplegia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SPG4 patients

CANTAB

Intervention Type DIAGNOSTIC_TEST

CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)

MOCA

Intervention Type DIAGNOSTIC_TEST

Montreal cognitive assessment (MOCA) in German

Healthy controls

CANTAB

Intervention Type DIAGNOSTIC_TEST

CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)

MOCA

Intervention Type DIAGNOSTIC_TEST

Montreal cognitive assessment (MOCA) in German

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CANTAB

CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)

Intervention Type DIAGNOSTIC_TEST

MOCA

Montreal cognitive assessment (MOCA) in German

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with SPG4 with known SPAST-Mutation (patient group) or healthy control
* Age 18 to 70 years
* Written, informed consent

Exclusion Criteria

* Lack of ability for a written, informed consent
* Presence of gait disorder or other neurological condition (for healthy controls)
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Tuebingen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Dr. Ludger Schöls

Prinicipal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ludger Schöls, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

University Hospital Tübingen, Center for Neurology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Tübingen, Center for Neurology

Tübingen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Rattay TW, Boldt A, Volker M, Wiethoff S, Hengel H, Schule R, Schols L. Non-motor symptoms are relevant and possibly treatable in hereditary spastic paraplegia type 4 (SPG4). J Neurol. 2020 Feb;267(2):369-379. doi: 10.1007/s00415-019-09573-w. Epub 2019 Oct 23.

Reference Type RESULT
PMID: 31646384 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Cognition_SPG4

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

nTMS for Motor Mapping of Rolandic Lesions
NCT02879682 COMPLETED PHASE2/PHASE3